Health Care [ 6/12 ] | Pharmaceuticals [ 37/73 ]
NYSE | Common Stock
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
It operates through Commercial Operations and Total R&D segments.
The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus.
Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases.
The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 29, 25 | 1.20 Increased by +10.42% | 1.04 Increased by +15.64% |
| Feb 5, 25 | 0.58 Decreased by -19.56% | 0.49 Increased by +18.79% |
| Oct 30, 24 | 1.29 Increased by +0.78% | 1.23 Increased by +4.88% |
| Jul 31, 24 | 1.10 Increased by +13.40% | 0.99 Increased by +11.11% |
| May 1, 24 | 1.09 Increased by +21.11% | 0.91 Increased by +19.78% |
| Jan 31, 24 | 0.72 Increased by +18.03% | 0.76 Decreased by -5.26% |
| Nov 1, 23 | 1.28 Increased by +16.36% | 1.14 Increased by +12.28% |
| Jul 26, 23 | 0.97 Increased by +11.49% | 0.87 Increased by +11.49% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 7.52 B Increased by +2.08% | 1.62 B Increased by +55.26% | Increased by +21.61% Increased by +52.10% |
| Dec 31, 24 | 8.12 B Increased by +0.81% | 414.00 M Increased by +18.29% | Increased by +5.10% Increased by +17.34% |
| Sep 30, 24 | 8.01 B Decreased by -1.66% | -58.00 M Decreased by -103.96% | Decreased by -0.72% Decreased by -104.03% |
| Jun 30, 24 | 7.88 B Increased by +9.84% | 1.17 B Decreased by -27.77% | Increased by +14.88% Decreased by -34.24% |
| Mar 31, 24 | 7.36 B Increased by +5.93% | 1.05 B Decreased by -29.80% | Increased by +14.21% Decreased by -33.73% |
| Dec 31, 23 | 8.05 B Increased by +9.16% | 350.00 M Decreased by -76.04% | Increased by +4.35% Decreased by -78.06% |
| Sep 30, 23 | 8.15 B Increased by +4.06% | 1.46 B Increased by +87.93% | Increased by +17.97% Increased by +80.60% |
| Jun 30, 23 | 7.18 B Increased by +3.59% | 1.62 B Increased by +93.79% | Increased by +22.62% Increased by +87.07% |